Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du, Xiang Guo, Miao Wang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

New and Emerging Targeted Therapies for Advanced Breast Cancer
Kristie Lau, Alexandra M. Tan, Yihui Shi
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2288-2288
Open Access | Times Cited: 106
CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
Lisa Crozier, Reece Foy, Brandon L. Mouery, et al.
The EMBO Journal (2022) Vol. 41, Iss. 6
Open Access | Times Cited: 86
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 46
Benzimidazoles in Drug Discovery: A Patent Review
Christine Shing Wei Law, Keng Yoon Yeong
ChemMedChem (2021) Vol. 16, Iss. 12, pp. 1861-1877
Closed Access | Times Cited: 65
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer
Panagiotis A. Konstantinopoulos, Elizabeth K. Lee, Niya Xiong, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 3, pp. 599-608
Closed Access | Times Cited: 46
Prospects of tangeretin as a modulator of cancer targets/pathways
Waseem Raza, Suaib Luqman, Abha Meena
Pharmacological Research (2020) Vol. 161, pp. 105202-105202
Closed Access | Times Cited: 56
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
Raymond Traweek, Brandon Cope, Christina L. Roland, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 33
Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus
J. Koch, Sebastian Johannes Schober, Sruthi V. Hindupur, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma
Danni Cheng, Ke Qiu, Yufang Rao, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 21
A critical review of benzimidazole: Sky-high objectives towards the lead molecule to predict the future in medicinal chemistry
Sabyasachi Banerjee, Sougata Mukherjee, Priyobrata Nath, et al.
Results in Chemistry (2023) Vol. 6, pp. 101013-101013
Open Access | Times Cited: 18
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Seth A. Wander, Neil A. O’Brien, Lacey M. Litchfield, et al.
The Oncologist (2022) Vol. 27, Iss. 10, pp. 811-821
Open Access | Times Cited: 26
Gold Nanoparticle-Mediated Gene Therapy
Gayathri A. Kanu, Javad B. M. Parambath, Raed O. Abu Odeh, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5366-5366
Open Access | Times Cited: 24
The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
Mary Abdelmalak, Rajanbir Singh, Mohammed Anwer, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5388-5388
Open Access | Times Cited: 24
The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
Aadil Javed, Mahdieh Yarmohammadi, Kemal Korkmaz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2848-2848
Open Access | Times Cited: 14
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Georgia Gomatou, Ioannis Trontzas, Stephanie Ioannou, et al.
Molecular Biology Reports (2021) Vol. 48, Iss. 1, pp. 915-925
Closed Access | Times Cited: 30
CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade
Jingshan Tong, Xiao Tan, Xiangping Song, et al.
Cancer Research (2022) Vol. 82, Iss. 7, pp. 1340-1352
Open Access | Times Cited: 21
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Nischal Koirala, Nandini Dey, Jennifer C. Aske, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6547-6547
Open Access | Times Cited: 20
Carvacrol as a Prospective Regulator of Cancer Targets/Signalling Pathways
Jyoti Singh, Suaib Luqman, Abha Meena
Current Molecular Pharmacology (2022) Vol. 16, Iss. 5
Closed Access | Times Cited: 20
Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool
Rinka Nakajima, Lin Zhao, Yaxuan Zhou, et al.
Genes (2023) Vol. 14, Iss. 2, pp. 393-393
Open Access | Times Cited: 12
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov
Jing Yang, Heming Kang, Liyang Lyu, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis
Xiaogang Li, Chao Niu, Guoqiang Yi, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0305612-e0305612
Open Access | Times Cited: 4
Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
Lin Jia, Junning Peng, Nan Sun, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations
Kyoo Hyun Kim, Changhee Park, Seung‐Hoon Beom, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104106-104106
Closed Access
Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer
Xue Wei, Ming Yang, Haoyang Zou, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 760-772
Closed Access
Targeting CDK4/6 suppresses colorectal cancer by destabilizing YAP1
Yalei Wen, Xiao Yang, Shengrong Li, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Page 1 - Next Page

Scroll to top